Sandoz has launched ferumoxytol iron deficiency anaemia (IDA) treatment in the US and pemetrexed oncology treatment in Europe.
US ferumoxytol launch
Sandoz announced the immediate availability of its generic ferumoxytol, in the US from mid July 2021. Ferumoxytol is an intravenous medicine used to treat IDA and is a generic equivalent to AMAG Pharmaceuticals’ Feraheme® (ferumoxytol injection).
Initially, Sandoz’s ferumoxytol will be available to patients in the hospital and clinic setting. It is approved to treat IDA in adults who have an intolerance to oral iron, have an unsatisfactory response to oral iron, or those with chronic kidney disease. It is hoped that this product will deliver a more cost-effective treatment option to brand-name products for patients in the US.
European pemetrexed launch
Sandoz’s ferumoxytol launch follows the June announcement that Sandoz will launch the generic oncology treatment pemetrexed in 11 countries across Europe, including Germany, Switzerland, The Netherlands and Spain.
Pemetrexed is a treatment for non-small cell lung cancer (NSCLC) and plural mesothelioma, a cancer of the lung lining most often caused by inhaling asbestos [1]. In 2020, there were over 26,000 deaths from mesothelioma globally, and approximately 2.2 million new cases of lung cancer including 31,000 new cases of mesothelioma were diagnosed.
Pemetrexed can be used as a monotherapy or in combination with cisplatin. Alimta produced the first generic version of Eli Lilly’s originator pemetrexed product to be approved in Europe in 2018 [2]. Sandoz’s new product is now available in a ready-to-dilute format and in an additional, higher-strength dosage. It is hoped that this will provide patients with a lower cost treatment option and both patients and physicians will benefit from the reduced preparation steps required. In the hospital, patients receive the treatment via a 10-minute intravenous infusion.
Related articles
Zydus Cadila and Sandoz generics approvals in North America
Generic diabetes and cancer drugs pose challenge to Bristol Myers Squibb and Eli Lilly
FDA issues final guidance on liposome drug products
Generics applications under review by EMA January 2018
| LATIN AMERICAN FORUM The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: Biosimilares e intercambiabilidad en oncología Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: Biosimilares e intercambiabilidad en oncología Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. FDA approves lung cancer and anticoagulant generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3]. Available from: www.gabionline.net/generics/news/FDA-approves-lung-cancer-and-anticoagulant-generics
2. GaBI Online - Generics and Biosimilars Initiative. Generics applications under review by EMA June 2018 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3]. Available from: www.gabionline.net/generics/general/Generics-applications-under-review-by-EMA-June-2018
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment